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Detection of an oestrogen receptor-like protein in human meningiomas by
band shift assay using a synthetic oestrogen responsive element (ERE)
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Department ofEndocrinology, Academic Hospital Utrecht, Utrecht, The Netherlands.
Summary When a ligand binding or enzyme immunoassay is used, meningiomas are found to be rich in
progestin receptors (PR) whereas oestrogen receptors (ER) are virtually undetectable. A protein that can bind
to an oestrogen responsive element (ERE) was detected in meningiomas, by using the band-shift assay. The
binding of ER to the ERE is inhibited by the anti-ER monoclonal antibody ER-P31, which is directed to the
A/B domain of the ER, indicating that the binding protein is an ER-like protein.
Female sex hormones may be involved in the etiology of
human meningioma. Following the first report in 1979, on
the putative presence of oestrogen receptors (ER) in human
meningiomas (Donnell et al., 1979), several research groups,
including our own (Blankenstein et al., 1983; Martuza et al.,
1985) have tried to confirm these findings. Using Scatchard
plot analysis (Blaauw et al., 1986) or enzyme immunoassay
(Blankenstein et al., 1987) the majority of meningiomas were
found to be ER negative. The same experiments revealed that
meningiomas contain high amounts of progestin receptors
(PR). Since in classical female sex steroid target tissues like
breast and uterus, the synthesis of PR is ER dependent the
finding that (at the protein level at least) meningiomas are
rich in PR, yet virtually devoid of ER initiated further
research.
We recently reported on the detection of mRNA coding
for the wild type receptor by using the reversed-transcriptase-
PCR technique (Koehorst et al., 1992). Apart from the wild
type (wt) mRNA we also found two alternatively spliced
mRNA's. One variant is missing exon 4 and the other is
missing exon 7 (Koehorst et al., 1993).
The present study was designed to evaluate the presence in
meningiomas of ER or ER-like proteins which could induce
PR synthesis. We hypothesised that if the ER (at concentra-
tions below the detection limit of the conventional receptor
assay) or ER-like protein (escaping detection by lack of
ligand binding) is responsible for the induction of PR syn-
thesis in meningiomas at least a protein should be present
which can bind to the oestrogen responsive element (ERE) of
the PR-gene. The aim of the present investigation, therefore,
was to test if such an ERE-binding protein is present in
meningioma. To this end the binding of meningioma cytosol
components to a synthetic ERE was investigated with the
band shift assay. This assay is a very sensitive method to
detect ERE binding proteins. Scott et al. (1991) could detect
as little as 0.1 fmol of DNA bound ER from whole cell
extracts containing 50 lg protein.
We found evidence for the existence of a protein that binds
to the ERE and is recognised by the specific anti-ER
antibody ER P31.
Materials and methods
Tissues
Human meningioma tissue was placed on ice immediately
after removal from the patient. Representative specimens
were frozen at - 80'C until they were used for cytosol
preparation or receptor assay. The MCF7 breast cancer cell
line was routinely grown with 10% foetal calf serum (Gibco
BRL, Paisely, UK) with RPMI 1640 (Gibco BRL, Paisely,
UK). Cells were harvested by scraping with a rubber
policeman in PBS.
Biochemical assay ofsteroid hormone binding
The ER and PR content of the tumours were measured as
described previously (Blankenstein et al., 1983) by the ligand
binding assay according to the guidelines of the EORTC,
Breast Cancer Cooperative Group (EORTC, Breast Cancer
Cooperative Group, 1980).
Cytosolpreparationfor ERE-binding experiment
Approximately 400 mg of fresh tissue powder was added to
1.5 ml of ice cold extraction buffer (0.4 M KCI, 10 mM Tris
(pH 7.4), 1 mM EDTA, 10 mM monothioglycerol, 10%
glycerol (v/v)) or 20 x 106MCF7 cells were dounced in
1.5 ml ice cold extraction buffer. The resulting homogenate
was centrifuged for 5 min at 4'C at 3,600 r.p.m. The super-
natant was centrifuged again in a swing out rotor at
132,000 g for 10min at 4°C. Twenty-fivepl of the clear
supernatant was used for protein determination by the
Coomassie Brilliant Blue method (Biorad, Richmond, CA,
USA).
Bandshift assay
As probe for the band shift assay, we chose the ERE from
the vitellogenin A2 gene which has been shown to have high
regulatory potential in transient transfection of ERE-
TKCAT reporter construction into oestrogen responsive
MCF7 cells (Klein-Hitpass et al., 1986). Both strands corres-
ponding to the ERE were synthesised as 31 (5'-
GATCCGTCAGGTCACAGTGACCTGATGGATC-3'; palin-
drome is underlined) base oligonucleotides using an Applied
Biosystems DNA synthesiser (San Jose, CA, USA).
Equimolar amounts of the two strands were annealed in
buffer (10 mM Tris, 1 mM EDTA (pH 8.0)) by heating to
95'C and cooling to room temperature during a period of
2 h. The double stranded ERE oligomer was end-labelled
using [6_32P] ATP (Amersham, Amersham, UK) and T4
polynucleotide kinase (Boehringer Mannheim, Mannheim,
Germany). Fivetl of the supernatant containing 20-30 ig
protein (for MCF7 containing 2 Ig of protein) were added to
151Al incubation buffer (100 mMTris (pH 8.0), 1 mM EDTA,
10% glycerol (v/v), 2ytg poly(dI.dC)) and placed on ice.
After 15 min 1 ng 32P-labelled double-stranded ERE oligomer
was added and the reaction mixture incubated for 20 min at
20'C. The protein-ERE complexes were separated by elect-
rophoresis through 6% acrylamide (19:1, acrylamide;bis) gels
using a buffer consisting of 50 mM Tris, 50 mM boric acid,
1 mM EDTA (pH 8.0). The gels were run at 180 V for 3 h,
vacuum dried and autoradiographed. The ER-containing
human breast cancer cell line MCF7 was used as a positive
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control for ERE binding.
To confirm the integrity of the protein isolated from the
tumours, a band shift assay was performed using a
oligonucleotide which contained the Spl binding consensus
sequence (5'-CAAAGTCTGGGCGGGCCGATCAAG-'3; con-
sensus is underlined). For the competition binding analysis in
which the specificity of the ERE was proven, a
oligonucleotide was used which contained the consensus of
the progesterone responsive element (PRE)(5'-CCAAA-
GTCAGAACACAGTGTTCTGATCAAG-3'; palindrome is
underlined and differences with palindrome of ERE are in
bold underlined).
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Results
The ERE from the vitellogenin A2 gene which was used in
the band shift assay has proven specificity in oestrogen bind-
ing experiments (Klein-Hitpass et al., 1988; 1989; Klock et
al., 1987).
The specificity of binding of the ERE oligonucleotides to
ER in crude, high salt extracts from MCF7 and meningioma
is shown in Figure 1. The intensity of the ER-ERE complex
decreases with increasing ratios of unlabelled/labelled ERE,
while the intensity of the ER-ERE complex is unaffected with
increasing molar excess of PRE (Figure la and b). When
MCF7 cytosol was run together with the meningioma sample
a single, prominent band co-migrating with that obtained
from MCF7 whole cell extract was observed. We attribute
this result to the presence of ER or an ER-like protein in the
meningioma tissue.
To identify the ER in the ER-ERE complex, cytosols were
incubated with the anti-ER monoclonal antibody ER-P31
(MEDAC, Hamburg, Germany). This antibody inhibits the
binding to the ERE of the ER from MCF7 cells as well as
the ER-like protein in the two meningiomas and the ER in
solid breast tumours (Figure 2).
After we had proven the specificity of this ERE
oligonucleotide under our experimental conditions, we tested
15 meningiomas with different ER and PR concentration. In
all meningiomas but one, including the meningiomas which
were ER negative in the ligand binding assay, we could
detect a protein which can bind to ERE oligonucleotide
(Figure 3, upper panel). The ERE-protein complex from the
meningiomas co-migrates with the MCF7 ER-ERE complex
even in gels run for longer times (data not shown). To check
the integrity of the isolated protein all the meningiomas were
tested for SpI binding and all except one were found to be
positive (Figure 3, lower panel). This meningioma extract
also failed to show ERE-binding. We also checked the ER-
ERE binding in meningiomas and the normal meninges from
F -_
Figure 1 Binding specificity ofthe ERE oligonucleotide in crude,
high salt extracts from MCF7 cells and meningioma tissue. Com-
petition binding analysis was performed in which extracts from
MCF7 cells a, and meningioma tissue b, were incubated with 1 ng
of 32P-labelled ERE and increasing amounts of unlabelled ERE
as specific competitor or unlabelled PRE as nonspecific com-
petitor as reflected in the molar ratio indicated above each
lane.
two patients. An ER-ERE complex was detectable in menin-
giomas, the normal meninges were negative for ER-ERE
binding. However the normal meninges was also negative for
Spl binding and therefore these results do not allow con-
clusions to be drawn on differences between normal and
tumour tissue.
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Figure 2 Anti-ER monoclonal antibody ER-P31 reduces ERE-
protein complex in crude, high salt extracts. The extracts were
first incubated with 5fig antibody ER-P31 or nonspecific
antibody (anti-C peptide) at 4°C for 18 h. After administration of
I ng labelled ERE, the mixture was incubated for 30 min at room
temperature and separated on a 6% gel. Extracts from MCF7
cells, an ER +/PR + and ER - /PR + meningioma tissue, and
ER +/PR + breast cancer were used. The ER and PR levels are
given as fmol/mg protein. (F: protein-free ERE).292 S.G.A. KOEHORST et al.
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Figure 3 Analysis of ERE-binding activity a, and Spl-binding activity b, of extracts from 13 meningioma tissues; meningioma
tissue (M) and normal meninges (A) from two patients (patient 1 and 2); two normal meninges (Arachn.) and MCF7 (C) as control
in the far right and left lanes for the mobility shift assay. The ER and PR levels indicated under each lane are given as fmol/mg
protein. (F; protein-free ERE). ERE and Spl binding concur, indicating the integrity of MCF7 and most meningioma extracts but
not the normal meninges extracts.
Discussion
The abundant presence of PR in meningioma and the
absence of ER measured by ligand binding assay or enzyme
immunoassay prompted us to search for the ER or ER-like
protein in meningioma using other techniques. We have
already detected mRNA coding for the ER in meningioma
(Koehorst et al., 1992). Besides the wild type transcript two
variants were detected, one missing exon 7 and the other
missing exon 4 (Koehorst et al., 1993). If the wt transcript or
the variants are responsible for the PR synthesis, we
hypothesise that a protein has to be present which can bind
to an ERE.
We analysed DNA-binding activity to the ERE in human
meningiomas by a gel mobility assay. The promotor regions
of the PR gene are under investigation to define the func-
tional ERE in this gene. So far two functional promotor
regions have been described to be important for the induc-
tion of PR synthesis by ER. These two regions showed
oestrogen inducibility in transient co-transfection experiments
with vectors expressing the human ER, although no 'clas-
sical' ERE was detected in these promotor regions (Kastner
et al., 1990). The sequences which are responsible for this ER
inducibility are not well defined. Since no classical ERE is
present in the promoter region of the PR gene and as the
functional ERE in these regions is not well defined we
a
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decided to use a 'classical' ERE from the Xenopus vitel-
logenin A2 gene. This element has been shown to be specific
in several band-shift experiments performed by other groups
(Klein-Hitpass et al., 1989). We used MCF7 cells as a
positive control and demonstrated that the ER-ERE complex
derived from meningioma extracts co-migrated with the com-
plex obtained from whole cell extracts of MCF7 cells. The
anti-ER monoclonal antibody ER-P31 was able to
specifically block ER-ERE complex formation, demon-
strating the presence of ER in the complex from MCF7 cells,
meningiomas and solid breast cancer derived cytosol (Figure
2). This antibody has been used before in immunohisto-
chemistry (Wilkinson et al., 1988). ER-P31 gives intense
nuclear staining on frozen sections of breast carcinoma. Bind-
ing of the antibody to ER was confirmed by displacement
assays of the receptor on a sucrose gradient (Wilkinson et al.,
1988; Wong et al., 1991). The epitope which is recognised by
ER-P31 is located in the A/B domain of the receptor. Since
this is the variable part of the receptor recognition of ERR-1
or ERR-2 is very unlikely. This antibody inhibits the DNA
binding activity of ER. Therefore in the present experiments
incubation with antibody was carried out first, followed by
incubation with the ERE. If incubation with the ERE is
performed first, the antibody hardly interferes with DNA
binding of ER. Following binding to the ERE the epitope on
the ER is probably no longer accessible to the antibody.
Based on the considerations above, we conclude that the
ERE used is specific.
We tested 15 meningiomas for the presence of proteins
binding to the ERE. The receptor phenotype of these menin-
giomas ranged from ER/PR positive, ER-negative/PR-
positive to ER/PR negative. All but one of the meningiomas
were positive for ER-ERE binding, including the ER/PR
negative meningiomas (Figure 3, upper panel). This suggests
that the protein detected is by itself not sufficient to induce
PR synthesis in meningiomas.
It is tempting to speculate that this ER or ER-like protein
plays a role in the development and growth of the menin-
gioma and biosynthesis of PR. To test the tumour specificity
of the ERE binding, meningiomas and normal meninges
from two patients were used. The two meningiomas were
positive for ER-ERE binding and also positive for Spl bind-
ing (Figure 3). The normal meninges however were negative
for both. This can be attributed to the fact that normal
meningeal tissue is a quiescent tissue. This is confirmed by
the fact that we also were not able to isolate any intact
mRNA from the normal meninges. Thus the normal men-
inges cannot be used as a control in this assay and no
conclusions can be drawn about the tumour specificity of the
ER-ERE binding.
The band shift assay results shown here apparently are in
disagreement with those from the ligand binding assay ob-
tained in the past. From experiments with breast tumours it
is known however that the band shift assay is not always in
agreement with the ligand binding assay. Foster et al. (1991)
tested 79 breast tumours of which 55 showed that the band
shift assay was in agreement with the hormone-binding assay.
In 13 tumours the hormone binding assay was negative
whereas the band shift assay was positive. In two cases a
ER-negative/PR-positive tumour was tested, in both cases the
band shift assay was positive (Foster et al., 1991). These two
cases have resemblance with the phenotype of meningiomas
which are mostly also ER-negative/PR-positive.
In meningiomas an ER or ER-like protein is detectable by
the band shift assay but not detectable by ligand-binding
(Blaauw et al., 1986) or by enzyme immunoassay (Blanken-
stein et al., 1987). This may be due to the sensitivity of the
assay (Scott et al., 1991).
Another explanation could be a mutation in the hormone-
binding domain of the ER so that such an ER variant would
not be detected by the ligand binding assay and probably
also not in the immunoassay. For example in ER-/PR+
breast tumours an ER variant was detected missing exon 5.
This variant was constitutively active in a trans-activation
assay (Fuqua et al., 1991). We detected in meningiomas two
variant ER mRNA species (Koehorst et al., 1993). One
variant with a major deletion in the ligand binding domain
was an alternatively spliced product missing exon 7. This
variant has no hormone independent transcriptional activity
as shown by McGuire et al. (1991). Therefore this variant
can probably not account for the apparently autonomous PR
synthesis in meningiomas. The variant missing exon 4 codes
for ER missing amino acid 254-365. Exon 4 includes the last
part of the DNA binding domain, the hinge region and the
first hundred amino acids of the ligand binding domain. The
two zinc fingers of the DNA binding domain are intact so
DNA binding can probably occur but no oestradiol will be
bound by this variant because a great part of the ligand
binding domain is missing. In addition, the highly positively
charged region situated between amino acid 251 and 271 is
missing. This sequence is very important for the formation of
the non-DNA binding 8-9 S ER complexes, which bind heat
shock protein 90 (hsp 90) (Chambraud et al., 1990). A
variant missing amino acids 251-271 such as the variant
missing exon 4 can probably not bind hsp 90 and therefore is
always in the 4-5 S DNA binding form. This variant could
play a role but whether it is capable oftransactivation as well
as its relationship to the ER-like protein described here
remain to be investigated.
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